198 related articles for article (PubMed ID: 9755724)
1. Radiation-activated prodrugs as hypoxia-selective cytotoxins: model studies with nitroarylmethyl quaternary salts.
Wilson WR; Tercel M; Anderson RF; Denny WA
Anticancer Drug Des; 1998 Sep; 13(6):663-85. PubMed ID: 9755724
[TBL] [Abstract][Full Text] [Related]
2. Radiolytic and cellular reduction of a novel hypoxia-activated cobalt(III) prodrug of a chloromethylbenzindoline DNA minor groove alkylator.
Ahn GO; Botting KJ; Patterson AV; Ware DC; Tercel M; Wilson WR
Biochem Pharmacol; 2006 Jun; 71(12):1683-94. PubMed ID: 16620789
[TBL] [Abstract][Full Text] [Related]
3. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.
Wilson WR; Hicks KO; Pullen SM; Ferry DM; Helsby NA; Patterson AV
Radiat Res; 2007 Jun; 167(6):625-36. PubMed ID: 17523848
[TBL] [Abstract][Full Text] [Related]
4. Nitro reduction as an electronic switch for bioreductive drug activation.
Siim BG; Denny WA; Wilson WR
Oncol Res; 1997; 9(6-7):357-69. PubMed ID: 9406242
[TBL] [Abstract][Full Text] [Related]
5. Reduction of nitroarylmethyl quaternary ammonium prodrugs of mechlorethamine by radiation.
Wilson WR; Ferry DM; Tercel M; Anderson RF; Denny WA
Radiat Res; 1998 Mar; 149(3):237-45. PubMed ID: 9496886
[TBL] [Abstract][Full Text] [Related]
6. Pathways of reductive fragmentation of heterocyclic nitroarylmethyl quaternary ammonium prodrugs of mechlorethamine.
Kriste AG; Tercel M; Anderson RF; Ferry DM; Wilson WR
Radiat Res; 2002 Dec; 158(6):753-62. PubMed ID: 12452778
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of stable bidentate transition metal complexes of 1-(chloromethyl)-5-hydroxy-3-(5,6,7-trimethoxyindol-2-ylcarbonyl)-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline (seco-6-azaCBI-TMI) as hypoxia selective cytotoxins.
Milbank JB; Stevenson RJ; Ware DC; Chang JY; Tercel M; Ahn GO; Wilson WR; Denny WA
J Med Chem; 2009 Nov; 52(21):6822-34. PubMed ID: 19821576
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia-selective antitumor agents. 16. Nitroarylmethyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine.
Tercel M; Lee AE; Hogg A; Anderson RF; Lee HH; Siim BG; Denny WA; Wilson WR
J Med Chem; 2001 Oct; 44(21):3511-22. PubMed ID: 11585455
[TBL] [Abstract][Full Text] [Related]
9. Chemical radiosensitizers for use in radiotherapy.
Wardman P
Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):397-417. PubMed ID: 17478086
[TBL] [Abstract][Full Text] [Related]
10. Failla Memorial Lecture. Redox, radiation, and reductive bioactivation.
Adams GE
Radiat Res; 1992 Nov; 132(2):129-39. PubMed ID: 1438693
[TBL] [Abstract][Full Text] [Related]
11. Reductive activation of 5-fluorodeoxyuridine prodrug possessing azide methyl group by hypoxic X-irradiation.
Tanabe K; Ishizaki J; Ando Y; Ito T; Nishimoto S
Bioorg Med Chem Lett; 2012 Feb; 22(4):1682-5. PubMed ID: 22248856
[TBL] [Abstract][Full Text] [Related]
12. Antitumour prodrug development using cytochrome P450 (CYP) mediated activation.
Patterson LH; McKeown SR; Robson T; Gallagher R; Raleigh SM; Orr S
Anticancer Drug Des; 1999 Dec; 14(6):473-86. PubMed ID: 10834269
[TBL] [Abstract][Full Text] [Related]
13. AQ4N: a new approach to hypoxia-activated cancer chemotherapy.
Patterson LH; McKeown SR
Br J Cancer; 2000 Dec; 83(12):1589-93. PubMed ID: 11104551
[TBL] [Abstract][Full Text] [Related]
14. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.
Roy P; Waxman DJ
Toxicol In Vitro; 2006 Mar; 20(2):176-86. PubMed ID: 16293390
[TBL] [Abstract][Full Text] [Related]
15. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
Fourie J; Oleschuk CJ; Guziec F; Guziec L; Fiterman DJ; Monterrosa C; Begleiter A
Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423
[TBL] [Abstract][Full Text] [Related]
16. Optimization of the auxiliary ligand shell of Cobalt(III)(8-hydroxyquinoline) complexes as model hypoxia-selective radiation-activated prodrugs.
Ahn GO; Ware DC; Denny WA; Wilson WR
Radiat Res; 2004 Sep; 162(3):315-25. PubMed ID: 15333003
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia-activated prodrugs: substituent effects on the properties of nitro seco-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (nitroCBI) prodrugs of DNA minor groove alkylating agents.
Tercel M; Atwell GJ; Yang S; Stevenson RJ; Botting KJ; Boyd M; Smith E; Anderson RF; Denny WA; Wilson WR; Pruijn FB
J Med Chem; 2009 Nov; 52(22):7258-72. PubMed ID: 19877646
[TBL] [Abstract][Full Text] [Related]
18. Diflavin oxidoreductases activate the bioreductive prodrug PR-104A under hypoxia.
Guise CP; Abbattista MR; Tipparaju SR; Lambie NK; Su J; Li D; Wilson WR; Dachs GU; Patterson AV
Mol Pharmacol; 2012 Jan; 81(1):31-40. PubMed ID: 21984255
[TBL] [Abstract][Full Text] [Related]
19. N-Substituted 2-(2,6-dinitrophenylamino)propanamides: novel prodrugs that release a primary amine via nitroreduction and intramolecular cyclization.
Sykes BM; Atwell GJ; Hogg A; Wilson WR; O'Connor CJ; Denny WA
J Med Chem; 1999 Feb; 42(3):346-55. PubMed ID: 9986704
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia-selective activation of 5-fluorodeoxyuridine prodrug possessing indolequinone structure: radiolytic reduction and cytotoxicity characteristics.
Tanabe K; Makimura Y; Tachi Y; Imagawa-Sato A; Nishimoto S
Bioorg Med Chem Lett; 2005 May; 15(9):2321-4. PubMed ID: 15837317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
